title: [New antithrombotic drugs: fondaparinux, idraparinux, ximelagatran].
abstract: Antithrombotic drugs: heparins and oral vitamin K antimetabolites are connected with many side effects, which delimit their application in clinical practise. Continuous research has led to synthesis of new drugs which are safer and easier in use. Actually used antithrombotic drugs with their faults are discussed. Mechanism of action and data from trials relating to efficacy and safety of new drugs: fondaparinux, idraparinux and ximelagatran are presented.
authors.affiliation: Katedra Chorób Wewnetrznych i Gerontologii Collegium Medicum Uniwersytetu Jagiellońskiego. rewiuk@mp.pl
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Rewiuk
authors.forename: Paweł
authors.initials: P
authors.lastname: Franczuk
authors.forename: Tomasz
authors.initials: T
authors.lastname: Grodzicki
mesh_terms: D001384:Azetidines / Q000009:adverse effects / Q000627:therapeutic use*; D001596:Benzylamines / Q000009:adverse effects / Q000627:therapeutic use*; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077425:Fondaparinux; D006801:Humans; D009844:Oligosaccharides / Q000009:adverse effects / Q000627:therapeutic use*; D011134:Polysaccharides / Q000009:adverse effects / Q000627:therapeutic use*; D013927:Thrombosis / Q000517:prevention & control*
chemical_list: D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; D009844:Oligosaccharides; D011134:Polysaccharides; C426686:ximelagatran; C479958:idraparinux; D000077425:Fondaparinux